BTI
CORT icon

Blue Trust Inc’s Corcept Therapeutics CORT Stock Holding History

Blue Trust Inc’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4K Sell
419
-71
-14% -$4.29K ﹤0.01% 1476
2026
Q1 		$19.8K Sell
490
-584
-54% -$21.8K ﹤0.01% 1648
2025
Q4 		$37.4K Sell
1,074
-424
-28% -$33.3K ﹤0.01% 1460
2025
Q3 		$124K Buy
1,498
+43
+3% +$3.11K ﹤0.01% 980
2025
Q2 		$107K Sell
1,455
-890
-38% -$64.5K ﹤0.01% 1021
2025
Q1 		$268K Sell
2,345
-585
-20% -$35.6K ﹤0.01% 607
2024
Q4 		$148K Sell
2,930
-8,728
-75% -$457K ﹤0.01% 764
2024
Q3 		$379K Buy
11,658
+8,132
+231% +$289K ﹤0.01% 573
2024
Q2 		$88.8K Buy
3,526
+1,962
+125% +$53.7K ﹤0.01% 1025
2024
Q1 		$39.4K Buy
1,564
+1,177
+304% +$27.8K ﹤0.01% 993
2023
Q4 		$11K Buy
+387
New +$10.6K ﹤0.01% 1540
2023
Q3 		– Sell
-40
Closed -$1K – 2075
2023
Q2 		$1K Hold
40
– – ﹤0.01% 1822
2023
Q1 		$1K Buy
40
+10
+33% +$219 ﹤0.01% 2126
2022
Q4 		$1K Buy
+30
New +$752 ﹤0.01% 2031

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blue Trust Inc's CORT Position: Q2 2026 in Review

Blue Trust Inc reduced its Corcept Therapeutics (CORT) stake by 14% in Q2 2026, selling an estimated $4.29K and leaving 419 shares worth $36.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1476.

Blue Trust Inc first reported a position in CORT in Q4 2022 and has held it in 14 quarters since. The position peaked at $379K in Q3 2024. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Blue Trust Inc held 419 shares of Corcept Therapeutics worth $36.4K as of Q2 2026.
  • Blue Trust Inc sold 71 Corcept Therapeutics shares in Q2 2026, an estimated $4.29K.
  • Corcept Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1476 holding.
  • Blue Trust Inc first reported a position in Corcept Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Blue Trust Inc's Corcept Therapeutics position peaked at $379K in Q3 2024.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.